|
End-of-day quote
Shanghai S.E.
30/10/2026
|
5-day change | 1st Jan Change | ||
| 68.30 CNY | +1.85% |
|
-5.14% | +0.34% |
| 10-28 | Gan & Lee Pharmaceuticals Gets China Clinical Trial Nod for Atopic Dermatitis Treatment | MT |
| 10-28 | Gan & Lee Pharmaceuticals Posts Higher Q3 Attributable Profit; Revenue Up | MT |
| Market Cap | 40.66B 6.11B 5.47B 5.03B 4.56B 8.52B 580B 8.68B 60.02B 24.09B 305B 22.93B 22.44B 962B | P/E 2026 * |
28.7x | P/E 2027 * | 25.1x |
|---|---|---|---|---|---|
| Enterprise Value | 37.46B 5.63B 5.04B 4.64B 4.2B 7.85B 534B 8B 55.29B 22.19B 281B 21.12B 20.67B 886B | EV / Sales 2026 * |
7.51x | EV / Sales 2027 * | 6.34x |
| Free-Float |
57.94% | Yield 2026 * |
0.35% | Yield 2027 * | 0.4% |
| 1 day | +1.85% | ||
| 1 week | -5.14% | ||
| Current month | -11.76% | ||
| 1 month | -11.76% | ||
| 3 months | +0.59% | ||
| 6 months | +16.06% | ||
| Current year | +0.34% |
| 1 week | 65.5 |  | 72.88 |
| 1 month | 65.5 | | 78.27 |
| Current year | 51.51 | | 79.99 |
| 1 year | 51.51 | | 79.99 |
| 3 years | 32.1 | | 82.25 |
| 5 years | 30.53 | | 82.25 |
| 10 years | 30.53 | | 204.41 |
| Manager | Title | Age | Since |
|---|---|---|---|
Wei Chen
CEO | Chief Executive Officer | 46 | 30/05/2025 |
Qi Wang
DFI | Director of Finance/CFO | 44 | 09/03/2026 |
Ting Jia
CTO | Chief Tech/Sci/R&D Officer | - | 09/03/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Zhong Ru Gan
CHM | Chairman | 78 | 17/06/1998 |
Kai Du
BRD | Director/Board Member | 49 | 01/01/2010 |
Wei Qiang Song
BRD | Director/Board Member | 44 | 15/09/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/29/26 A | Sell | Director | -10,000 | 0.0019% | ||
| 9/29/26 A | Sell | Company Secretary | -15,000 | 0.0028% | ||
| 9/29/26 A | Sell | Chief Executive Officer | -5,000 | 0.0009% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.85% | -5.14% | -2.29% | +42.65% | 6.11B | |
| +3.19% | +11.31% | +67.86% | +150.58% | 1,263B | |
| -0.73% | +3.56% | +44.51% | +85.81% | 658B | |
| +1.41% | +3.24% | +29.22% | +107.83% | 521B | |
| +0.42% | +3.20% | +54.15% | +67.18% | 391B | |
| +2.18% | +2.93% | +73.30% | +45.62% | 369B | |
| +1.12% | +4.52% | +35.30% | +58.08% | 307B | |
| +6.96% | +8.86% | +11.27% | +36.62% | 290B | |
| +1.15% | +6.09% | +59.59% | +77.06% | 252B | |
| +3.06% | +9.38% | +44.11% | +119.47% | 212B | |
| Average | +1.74% | +4.79% | +41.70% | +79.09% | 426.8B | |
| Weighted average by Cap. | +1.19% | +6.58% | +50.80% | +98.23% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.98B 749M 671M 617M 559M 1.04B 71.11B 1.06B 7.36B 2.95B 37.41B 2.81B 2.75B 118B | 5.74B 863M 773M 711M 644M 1.2B 81.91B 1.23B 8.47B 3.4B 43.09B 3.24B 3.17B 136B |
| Net income | 1.43B 215M 192M 177M 160M 300M 20.4B 305M 2.11B 847M 10.73B 806M 789M 33.84B | 1.63B 244M 219M 201M 183M 341M 23.21B 348M 2.4B 964M 12.21B 918M 898M 38.51B |
| Net Debt | -3.2B -481M -431M -396M -359M -671M -45.69B -684M -4.73B -1.9B -24.03B -1.81B -1.77B -75.8B | -4.26B -639M -573M -527M -477M -892M -60.71B -909M -6.28B -2.52B -31.93B -2.4B -2.35B -101B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/10/26 | CN¥68.30 | +1.85% | 8,811,757 |
| 29/10/26 | CN¥67.06 | -1.47% | 7,169,100 |
| 28/10/26 | CN¥68.06 | -0.37% | 7,879,590 |
| 27/10/26 | CN¥68.31 | -5.14% | 8,910,143 |
| 26/10/26 | CN¥72.01 | +0.01% | 6,896,002 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 603087 Stock
Select your edition
All financial news and data tailored to specific country editions
